Julie Fisher, MD

Levine Cancer Institute

Charlotte, NC


HER2-positive Breast Cancer and COVID-19

November 19, 2021

Patient Jocelyn Mueller and oncologist Julia Fisher, M.D., describe some of the adjustments that had to be made to Jocelyn’s treatment for HER2-positive breast cancer due to the COVID-19 pandemic.

HER2-positive Breast Cancer: Post-Operative Therapies

October 29, 2021

Dr. Julie Fisher details the therapies used for HER2-positive breast cancer in the post-operative setting, including newly available treatment options, and reviews data supporting the choice of therapy for each patient.